Omeros Corp
OMER
Company Profile
Business description
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Contact
201 Elliott Avenue West
SeattleWA98119
USAT: +1 206 676-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
175
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
stocks
Cheap ASX share pays a heavy price for NRL rights
Growth has slowed amid increased competition for viewers and content.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,978.60 | 19.00 | -0.21% |
| CAC 40 | 8,364.65 | 25.69 | 0.31% |
| DAX 40 | 25,114.25 | 47.16 | 0.19% |
| Dow JONES (US) | 52,498.64 | 138.37 | -0.26% |
| FTSE 100 | 10,498.29 | 1.00 | 0.01% |
| HKSE | 24,099.89 | 113.83 | -0.47% |
| NASDAQ | 25,873.18 | 408.43 | -1.55% |
| Nikkei 225 | 67,214.33 | 28.40 | -0.04% |
| NZX 50 Index | 13,635.94 | 87.26 | -0.64% |
| S&P 500 | 7,515.34 | 60.05 | -0.79% |
| S&P/ASX 200 | 8,785.90 | 17.80 | -0.20% |
| SSE Composite Index | 3,887.92 | 25.87 | -0.66% |